BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38574101)

  • 1. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway.
    Samy AM; Kandeil MA; Sabry D; Abdel-Ghany AA; Mahmoud MO
    Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300631. PubMed ID: 38574101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.
    Kim TH; Lee Y; Lee YS; Gim JA; Ko E; Yim SY; Jung YK; Kang S; Kim MY; Kim H; Kim BH; Kim JH; Seo YS; Yim HJ; Yeon JE; Um SH; Byun KS
    Sci Rep; 2021 Jul; 11(1):14639. PubMed ID: 34282172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
    Loomba R; Quehenberger O; Armando A; Dennis EA
    J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Liu CH; Ampuero J; Gil-Gómez A; Montero-Vallejo R; Rojas Á; Muñoz-Hernández R; Gallego-Durán R; Romero-Gómez M
    J Hepatol; 2018 Dec; 69(6):1335-1348. PubMed ID: 30142428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
    Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
    JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating miRNAs associated with nonalcoholic fatty liver disease.
    Atic AI; Thiele M; Munk A; Dalgaard LT
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
    Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic TLR4 signaling in obese NAFLD.
    Sharifnia T; Antoun J; Verriere TG; Suarez G; Wattacheril J; Wilson KT; Peek RM; Abumrad NN; Flynn CR
    Am J Physiol Gastrointest Liver Physiol; 2015 Aug; 309(4):G270-8. PubMed ID: 26113297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
    Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD.
    du Plessis J; Korf H; van Pelt J; Windmolders P; Vander Elst I; Verrijken A; Hubens G; Van Gaal L; Cassiman D; Nevens F; Francque S; van der Merwe S
    PLoS One; 2016; 11(12):e0166048. PubMed ID: 27992443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
    PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of polymorphisms of adiponectin gene promoter-11377C/G, glutathione peroxidase-1 gene C594T, and cigarette smoking in nonalcoholic fatty liver disease.
    Zhang CX; Guo LK; Qin YM; Li GY
    J Chin Med Assoc; 2016 Apr; 79(4):195-204. PubMed ID: 26897098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia.
    Lee JW; Nam H; Kim LE; Jeon Y; Min H; Ha S; Lee Y; Kim SY; Lee SJ; Kim EK; Yu SW
    Autophagy; 2019 May; 15(5):753-770. PubMed ID: 30523761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.
    Wada N; Takaki A; Ikeda F; Yasunaka T; Onji M; Nouso K; Nakatsuka A; Wada J; Koike K; Miyahara K; Shiraha H; Yamamoto K; Okada H
    Hepatol Int; 2017 Jan; 11(1):115-124. PubMed ID: 27826704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.
    Wang Y; Liu Z; Zou W; Hong H; Fang H; Tong W
    Biomark Med; 2015; 9(11):1189-200. PubMed ID: 26506944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
    Morishita A; Oura K; Tadokoro T; Fujita K; Tani J; Kobara H; Ono M; Himoto T; Masaki T
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.